# US 2023/0265334 A1 · Treatment of Subterranean Formations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265334 A1
- Document ID: US20230265334A1
- Status: Published application
- Kind: A1
- Application number: 18/310,256
- Filed: 2023-05-01
- Published: 2023-08-24
- Earliest claimed: 2021-10-25
- Assignees: Saudi Arabian Oil Company; King Fahd University of Petroleum and Minerals
- Applicants: Saudi Arabian Oil Company; King Fahd University of Petroleum & Minerals
- Inventors: Rajendra Arunkumar Kalgaonkar; Eyad Alali; Mohammed A. Bataweel; Nisar Ullah; Muhammad Mansha
- Web page: https://patentgrep.com/patent/US20230265334A1

## CPC

- C09K 8/508: macromolecular compounds {(C09K8/512 takes precedence)}
- C09K 8/5086: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds}
- E21B 33/138: Plastering the borehole wall; Injecting into the formation
- C09K 2208/10: Nanoparticle-containing well treatment fluids
- C09K: MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- E21B: EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS

## Abstract

A method, wellbore, and pill for treating a region of a subterranean formation adjacent a wellbore zone of the wellbore, including injecting a gellable treatment composition (e.g., as the pill) through the wellbore zone into the region of the subterranean formation adjacent the wellbore zone, allowing the gellable treatment composition to form nanoparticles in-situ in the region and gel in the region via heat provided by the region to prevent or reduce flow of an unwanted fluid from the region into the wellbore zone. The gellable treatment composition may include a zwitterionic gemini surfactant (ZGS).

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A wellbore in a subterranean formation, the wellbore comprising a wellbore zone having a gel that restricts flow of fluid from the subterranean formation into the wellbore at the wellbore zone, wherein the gel comprises zwitterionic gemini surfactant and silica nanoparticles, wherein the silica nanoparticles are formed in situ from orthosilicate catalyzed by an acid.

### Claim 13 (depends on 12)

The wellbore of claim 12, wherein the zwitterionic gemini surfactant comprises:
wherein n1=8 to 18, n2=3 to 6, and n3=3 or 4, and wherein the functional group R is a sulfonate group, a carboxylate group, an aldehyde group, or a hydroxyl group.

### Claim 14 (depends on 12)

The wellbore of claim 12, wherein the fluid comprises water or natural gas, or both.

### Claim 15 (depends on 12)

The wellbore of claim 12, wherein the gel prevents flow of fluid from the subterranean formation into the wellbore at the wellbore zone.

### Claim 16

A pill comprising
a pill as applied to a wellbore formed through Earth surface in a subterranean formation, the pill comprising:
a zwitterionic gemini surfactant (ZGS);
a salt;
an orthosilicate;
an acid; and
water.

### Claim 17 (depends on 16)

The pill of claim 16, wherein the ZGS comprises:
wherein n1=8 to 18, n2=3 to 6, and n3=3 or 4, and wherein the functional group R is a sulfonate group, a carboxylate group, an aldehyde group, or a hydroxyl group.

### Claim 18 (depends on 16)

The pill of claim 16, wherein the acid comprises hydrochloric acid.

### Claim 19 (depends on 16)

The pill of claim 16, wherein the orthosilicate comprises tetraethyl orthosilicate (TEOS) or tetramethyl orthosilicate (TMOS), or a combination thereof, wherein the salt comprises calcium chloride, sodium chloride, potassium chloride, sodium bromide, sodium citrate, or sodium salicylate, or any combinations thereof, and wherein as applied to the wellbore comprises as formulated at the Earth surface and as injected into the wellbore.

### Claim 20 (depends on 19)

The pill of claim 19, wherein concentration of the ZGS in the pill is in a range of 2.5 wt % to 10 wt %, wherein concentration of the salt in the pill is in a range of 5 wt % to 30 wt %, wherein concentration of the orthosilicate in the pill is in a range of 1 wt % to 10 wt %, wherein concentration of the acid in the pill is at least one molar equivalent to the orthosilicate, and wherein as injected into the wellbore comprises as pumped into the wellbore.
